Linked Life Data

20156769

Source:http://linkedlifedata.com/resource/pubmed/id/20156769

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-2-16
pubmed:abstractText
Bacterial and viral respiratory tract infections may trigger relapses in patients with PR3-positive vasculitis. Data have suggested that treatment with co-trimoxazole may be beneficial, because this antibiotic could act by eliminating the offending microbe and thereby stopping the initiating stimulus. GOAL AND METHODS: Prospective, randomized, placebo-controlled study of the efficacy of co-trimoxazole given 960 mg thrice weekly for 18 months in preventing relapses in patients with Wegener's granulomatosis (WG) in remission, after treatment with cyclophosphamide and prednisolone was conducted. Relapses and infections were assessed with predefined criteria based on clinical, laboratory, serological, microbiological, and histopathological findings. Sixteen patients were assigned to receive co-trimoxazole and 15 to receive placebo.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0949-2321
pubmed:author
pubmed:issnType
Print
pubmed:day
7
pubmed:volume
14 Suppl 4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
265-7
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement.
pubmed:affiliation
Primary Systemic Vasculitis Outpatient Clinic, Department of Family Medicine, Internal and Metabolic Diseases, Warsaw Medical University, Warsaw, Poland. kzycinska@poczta.fm
pubmed:publicationType
Journal Article, Randomized Controlled Trial